As the height of cold and flu season approaches, so does the increase of Respiratory Syncytial Virus, or RSV. But in the future, RSV may not be as common as it is now in children and eventually the entire population.
In Tuesday’s Baltimore Sun an article appeared regarding positive results in a trial at Johns Hopkins University for a vaccine against Respiratory Syncytial Virus, or RSV. Dr. Ruth Karron, who led the initial trial, is the director of the Center for Immunization Research and a professor at the Bloomberg School of Public Health in International Health.
If proven successful in future trials, the vaccine could make a sweeping change for children’s health worldwide. In the US, RSV often leads to hospitalization. But around the world it is estimated that nearly 200,000 children under the age of 5 die annually from RSV.
The vaccine is also exciting because it was created by removing a protein that genetically alters the RSV make up, preventing it from producing so many copies of itself. In addition, without the key protein, the virus produces more of the proteins that boost the immune system.
To read more on the impact this vaccination could have, read the full Baltimore Sun article.